Incyte, a biopharmaceutical business, has announced that it has acquired two new buildings in Wilmington, Delaware’s downtown area. It marks the company’s fourth expansion into the state since 2014. The company officials made a statement stating that the move is intended to promote future growth and consolidate teams operating in the United States.

Currently dispersed throughout Delaware and Chadds Ford, Pennsylvania, Incyte’s U.S. commercial and medical affairs teams will now be centered in the recently acquired facilities at 1100 North King Street and 1100 North French Street. In the upcoming days, it will likely accommodate more than 400 workers, including the global corporate office and the U.S. teams for dermatology and oncology.

The CEO of Incyte, Hervé Hoppenot, stressed the company’s dedication to innovation and community involvement in Delaware and praised state and local officials for their support. Governor John Carney praised Incyte as a success story for Delaware, highlighting the company’s good influence on people’s lives through research and the anticipated creation of jobs.

Wilmington’s corporate innovation record is well-known, so Mayor Mike Purzycki applauded Incyte’s choice to relocate there. He emphasized the company’s contribution to tackling global health issues as well as the anticipated financial gains.

At the moment, Incyte employs more than 2,500 people throughout North America, Europe and Asia, with about 1,200 of those people based in Wilmington and Chadds Ford. The business will continue to run its Technical Operations and Research and Development departments out of its current location at Augustine Cut-off in Alapocas.

Wilmington, North Carolina-based Incyte is dedicated to the discovery, development and commercialization of proprietary pharmaceuticals. The company has a strong pipeline of drugs in the Oncology and Inflammation & Autoimmunity domains, as well as a portfolio of first-in-class medications.